H. Lundbeck A/S (CPH:HLUN.B)
Denmark flag Denmark · Delayed Price · Currency is DKK
30.20
+0.02 (0.07%)
May 12, 2025, 4:59 PM CET
-12.67%
Market Cap 29.15B
Revenue (ttm) 22.00B
Net Income (ttm) 3.14B
Shares Out 991.23M
EPS (ttm) 3.17
PE Ratio 9.53
Forward PE 6.26
Dividend 0.95 (3.15%)
Ex-Dividend Date Mar 27, 2025
Volume 520,032
Average Volume 469,851
Open 30.00
Previous Close 30.18
Day's Range 29.00 - 30.28
52-Week Range 27.20 - 49.38
Beta 0.22
RSI 41.51
Earnings Date May 14, 2025

About H. Lundbeck

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomati... [Read more]

Sector Healthcare
Founded 1915
Employees 5,707
Stock Exchange Copenhagen Stock Exchange
Ticker Symbol HLUN.B
Full Company Profile

Financial Performance

In 2024, H. Lundbeck's revenue was 22.00 billion, an increase of 10.51% compared to the previous year's 19.91 billion. Earnings were 3.14 billion, an increase of 37.25%.

Financial Statements

News

There is no news available yet.